 Connection
Elizabeth McFarland to Drug Therapy, Combination
This is a "connection" page, showing publications Elizabeth McFarland has written about Drug Therapy, Combination.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.181 |
|
|
|
-
Smith C, Weinberg A, Forster JE, Levin MJ, Davies J, Pappas J, Kinzie K, Barr E, Paul S, McFarland EJ. Maternal Lopinavir/Ritonavir Is Associated with Fewer Adverse Events in Infants than Nelfinavir or Atazanavir. Infect Dis Obstet Gynecol. 2016; 2016:9848041.
Score: 0.107
-
Jao J, Yu W, Patel K, Miller TL, Karalius B, Geffner ME, DiMeglio LA, Mirza A, Chen JS, Silio M, McFarland EJ, Van Dyke RB, Jacobson D. Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors: results from the Pediatric HIV/AIDS Cohort Study. HIV Med. 2018 03; 19(3):175-183.
Score: 0.030
-
Smith C, Forster JE, Levin MJ, Davies J, Pappas J, Kinzie K, Barr E, Paul S, McFarland EJ, Weinberg A. Serious adverse events are uncommon with combination neonatal antiretroviral prophylaxis: a retrospective case review. PLoS One. 2015; 10(5):e0127062.
Score: 0.025
-
Weinberg A, Forster-Harwood J, Davies J, McFarland EJ, Pappas J, Kinzie K, Barr E, Paul S, Salbenblatt C, Soda E, Vazquez A, Levin MJ. Safety and tolerability of antiretrovirals during pregnancy. Infect Dis Obstet Gynecol. 2011; 2011:867674.
Score: 0.019
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|